Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline name new research head

GlaxoSmithKline name new research head

7th February 2006

GlaxoSmithKline (GSK) has announced that Dr Tadataka Yamada, chairman of research and development (R&D) is to retire.

Mr Yamada will be replaced by Moncef Slaoui when he retries in June and takes up the role of executive director at the global health program of the Bill & Melinda Gates Foundation.

Mr Slaoui is currently GSK’s senior vice president of worldwide business development and external alliances in R&D.

GSK chief executive Dr Jean-Pierre Garnier said: “Tachi has been a principal architect behind the transformation and dramatic improvement in GSK’s R&D productivity and he leaves GSK in a position of strength.

“We now have an impressive pipeline of innovative medicines that will benefit patients around the world and provide a strong platform for GSK’s future prosperity.

Dr Yamada said: “I am proud to have been part of GSK, a business that makes a real difference to millions of patients all over the world. Our R&D organisation is in excellent shape and I am confident that under Moncef’s leadership, GSK will continue to deliver many innovative medicines of significant value to patients.

“Moncef is an outstanding scientist and a charismatic leader. Most importantly he and I share a common commitment to the welfare of patients.”

Dr Garnier added that Mr. Slaoui combines “scientific acumen, sound business sense, and a fervent commitment to public health”.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.